AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02459847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Study NCT01795092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermatology Consultation
Description: A dermatology consultation will be conducted on patients randomized to this group.
Study NCT00791362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: National programme for accreditation and improvement of GP
Description: The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
Study NCT01852552 — intervention group
Intervention type: DEVICE
Intervention: transcatheter aortic valve implantation
Description: Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
Study NCT01852552 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic Valve Replacement
Description: Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
Study NCT04530266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Six minute walk test
Description: Assessment of walking related performance fatigability using six minute walk test
Study NCT04530266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Six minute walk test
Description: Assessment of walking related performance fatigability using six minute walk test
Study NCT06148428 — intervention group
Intervention type: PROCEDURE
Intervention: Laser in situ keratomileusis (LASIK)
Description: Patients were planned to undergo laser in situ keratomileusis. Local anesthesia was achieved by preservative-free oxybuprocaine hydrochloride 0.4% drops (a commonly used topical anesthetic due to its effectiveness in alleviating pain and ocular surface discomfort during the procedure). During surgery, the lights of the operating room were dimmed as much as possible and the surgeons spoke to the patients in a calm voice and explained what was happening. They also reassured the patients that the surgery was going as planned and would be over soon.~For patients undergoing (Microkeratome) MK-LASIK, a Moria 2 Microkeratome (Moria SA, Antony, France) was used to create the flap. For patients undergoing Femtosecond LASIK (FS-LASIK), the Allegretto Wave Light FS-200 femtosecond Laser (Alcon labs, Fort Worth, TX, USA) was used for flap creation.~Laser ablation was performed using WaveLight EX500 Excimer Laser (Alcon labs, Fort Worth, TX, USA) with a planned post-operative emmetropia.
Study NCT00854425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
Study NCT00396552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: refractory transcranial magnetic stimulation (rTMS)
Description: Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
Study NCT00396552 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham condition
Description: Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
Study NCT03726775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Infusion of durvalumab during RT and after RT during 6 months
Study NCT02224820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IdeS
Description: Doses are administered in ascending doses
Study NCT02181322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - low dose
Study NCT02181322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - medium dose
Study NCT02181322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - high dose
Study NCT02838836 — intervention group
Intervention type: PROCEDURE
Intervention: Study sample collection
Description: Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
Study NCT04336449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab - single intravenous infusion
Study NCT04336449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - single intravenous infusion
Study NCT03140072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9898
Description: In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
Study NCT03140072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
Study NCT06646328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous access
Description: Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
Study NCT06646328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous access
Description: Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
Study NCT06646328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pump-assisted circuit
Description: The pump-assisted circuit to be used will be Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany). EMIC2® Fresenius Medical Care high-flux synthetic membrane will be used
Study NCT06646328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump-assisted circuit
Description: The pump-assisted circuit to be used will be Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany). EMIC2® Fresenius Medical Care high-flux synthetic membrane will be used
Study NCT06646328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium
Description: Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
Study NCT06646328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Description: Regional citrate anticoagulation will be used in the other arm with an initial dose of 3 mmol/L and with a calcium reinfusion solution at an initial dose of 2 mmol/L, with adaptation of both infusions to the patient ionic calcium levels.
Study NCT06646328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and ultrafiltrate samples
Description: Blood samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit. The ultrafiltrate will be collected directly from the outlet of the hemofilter (ultrafiltrate concentration \[Cuf\]).~The samples will taken at the beginning of CRRT (T0) and at the following times: T0, Ci; after 60 min (T1) and after 24 hours (T2) of CRRT, Ci, Co and Cuf.~Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
Study NCT06646328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood and ultrafiltrate samples
Description: Blood samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit. The ultrafiltrate will be collected directly from the outlet of the hemofilter (ultrafiltrate concentration \[Cuf\]).~The samples will taken at the beginning of CRRT (T0) and at the following times: T0, Ci; after 60 min (T1) and after 24 hours (T2) of CRRT, Ci, Co and Cuf.~Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
Study NCT06648343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive cognitive and physical training
Description: The cognitive and physical training program consists of 25-35 minutes of cognitive training (memory, attention, visuospatial orientation) and 10-15 minutes of physical training (stretching, strength training, coordination, and aerobic exercise). Additionally, participants will be instructed to perform 30-40 minutes of aerobic exercise 3-4 times per week
Study NCT03523182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend.
Study NCT03523182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
Study NCT03523182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
Study NCT02851160 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview conducted by a clinical psychologist
Description: semi-structured interview conducted by a clinical psychologist
Study NCT02851160 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
Description: semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
Study NCT01737060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse total shoulder arthroplasty
Study NCT01737060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty
Study NCT01324219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staff
Description: Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
Study NCT01324219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident
Description: Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
Study NCT04650971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UniFluVec
Description: Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
Study NCT04641260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral
Study NCT03731559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG 50 mg OD with food
Description: Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
Study NCT03731559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG 50 mg BID
Description: Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
Study NCT04364802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Nasal Spray and Gargle
Description: Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.
Study NCT04364802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Nasal Spray and Gargle
Description: Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.
Study NCT04364802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Nasal Spray and Gargle
Description: Community members will receive a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at home.
Study NCT05277142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral motor training
Description: they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
Study NCT05277142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
Study NCT00656487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: double blind, placebo controlled, single 90 mg dose
Study NCT00656487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo
Study NCT00522691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral nerve stimulation
Description: sacral nerve stimulation for fecal incontinence
Study NCT04362540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
Study NCT02918435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE CARE
Description: The WE CARE (Well-child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
Study NCT04725058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Group Visit
Description: A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
Study NCT04725058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietitian Individual Visit
Description: Participant receives obesity management individually from a registered dietitian.
Study NCT04205409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03573960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules.
Study NCT02847143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal oxytocin or placebo
Description: nasal administration of oxytocin or palcebo 45 min befor fMRI session
Study NCT02847143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: FMRI during emotional image visualization
Study NCT02847143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachement scale interview (ASI)
Description: this scale is used to determine the attachement style of each participant
Study NCT02847143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychometric scales
Description: self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
Study NCT02908672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Will be administered as per the schedule described in individual arm.
Study NCT02908672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Placebo
Description: Will be administered as per the schedule described in individual arm.
Study NCT02908672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Will be administered as per the schedule described in individual arm.
Study NCT02908672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Will be administered as per the schedule described in individual arm.
Study NCT02908672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib Placebo
Description: Will be administered as per the schedule described in individual arm.
Study NCT04650971 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
Study NCT04924686 — intervention group
Intervention type: OTHER
Intervention: Observational studies, no intervention
Description: Observational studies, no intervention
Study NCT03814512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Sleep Intervention
Description: Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
Study NCT01636154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ixeris of sonchifolia Hance
Description: KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study NCT01636154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Panax notoginseng saponins
Description: Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study NCT01636154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
Description: KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
Study NCT01583075 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Circumferential pulmonary vein ablation
Description: Circumferential pulmonary vein ablation
Study NCT01583075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single ring pulmonary vein ablation
Description: single ring pulmonary vein ablation
Study NCT02163226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Treatment
Description: Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
Study NCT02163226 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: One Radiation Treatment
Description: 12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
Study NCT02163226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
Study NCT02163226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.